Wt1 peptide vaccine for the treatment of cancer



Yüklə 0,51 Mb.
Pdf görüntüsü
səhifə2/2
tarix15.04.2022
ölçüsü0,51 Mb.
#55449
1   2
oka2008

Document Outline

  • WT1 peptide vaccine for the treatment of cancer
    • Introduction
    • Identification of WT1 protein-derived CTL epitopes and in vitro generation of WT1-specific CTLs
    • Spontaneous immune responses against WT1 protein in cancer patients
    • Mouse in vivo models for WT1 peptide cancer vaccine
    • Clinical trials of WT1 peptide cancer vaccine
      • Clinical responses
        • Patients with myeloid malignancies, including AML and MDS
        • Patients with multiple myeloma (MM)
        • Patients with MDS, vaccinated with ‘very low dose’ of WT1 peptide
        • Patients with solid cancer
        • No damage to normal tissues by WT1 peptide vaccination
        • Immunological responses and their correlation with clinical responses
    • Perspectives
      • New target diseases for WT1-directed cancer immunotherapy
      • Enhancement of clinical efficacy and usefulness of WT1 peptide vaccine
      • Translational research and reverse-translational research
      • Evaluation of cancer vaccine-induced clinical responses
      • Appropriate clinical settings for cancer vaccine
    • Conclusion
    • Acknowledgements
    • References and recommended reading

Yüklə 0,51 Mb.

Dostları ilə paylaş:
1   2




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©www.azkurs.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin